{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:14:38Z","timestamp":1776899678416,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Allogeneic hematopoietic cell transplantation (allo-HCT)\n                                is a curative therapy for relapsed\/refractory and high-risk\n                                non-Hodgkin lymphoma (NHL). However, no large studies have evaluated\n                                allo-HCT utilization in elderly NHL patients (\u226565 years). Using the\n                                CIBMTR registry, we report a time-trend analysis of 727 NHL patients\n                                (\u226565 years) undergoing the first allo-HCT from 2000 to 2015 in the\n                                United States (US). Study cohorts were divided by time period:\n                                2000\u20132005 (<jats:italic>N<\/jats:italic>\u2009=\u200976) vs. 2006\u20132010\n                                    (<jats:italic>N<\/jats:italic>\u2009=\u2009238) vs. 2011\u20132015\n                                    (<jats:italic>N<\/jats:italic>\u2009=\u2009413). Primary outcome\n                                was overall survival (OS). Secondary outcomes included\n                                progression-free survival (PFS), relapse\/progression (R\/P), and\n                                non-relapse mortality (NRM). Median age at transplant, use of\n                                reduced-intensity conditioning, and graft source remained stable,\n                                while use of unrelated donors increased in the most current era. The\n                                1-year probabilities of NRM from 2000 to 2005 vs. 2006\u20132010 vs.\n                                2011\u20132015 were 24% vs. 19% vs. 21%, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.67). Four-year probability of R\/P\n                                was similar among the three cohorts: 48% (2000\u20132005), 40%\n                                (2006\u20132010), and 40% (2011\u20132015) (<jats:italic>p<\/jats:italic>\u2009=\u20090.39). The 4-year probabilities of PFS and OS\n                                (2000\u20132005 vs. 2006\u20132010 vs. 2011\u20132015) showed significantly\n                                improved outcomes in more recent time periods: 17% vs. 31% vs. 30%\n                                    (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) and 21% vs. 42%\n                                vs. 44% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001),\n                                respectively. Utilization of allo-HCT increased in elderly NHL\n                                patients in the US since 2000 with improving survival\n                                outcomes.<\/jats:p>","DOI":"10.1038\/s41408-019-0261-1","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T14:03:16Z","timestamp":1575381796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Allogeneic transplantation in elderly patients\n                            \u226565 years with non-Hodgkin lymphoma: a time-trend\n                            analysis"],"prefix":"10.1038","volume":"9","author":[{"given":"Nirav N.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Woo","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Litovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Inwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexsandr","family":"Lazaryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lazaros","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pashna","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman A.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"261_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.bbmt.2017.05.035","volume":"23","author":"A D'Souza","year":"2017","unstructured":"D'Souza, A., Lee, S., Zhu, X. & Pasquini, M.\n                                    Current use and trends in hematopoietic cell transplantation in\n                                    the United States. Biol. Blood Marrow\n                                        Transplant.\n                                    23, 1417\u20131421\n                                    (2017).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"261_CR2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1001\/jama.2011.1558","volume":"306","author":"ML Sorror","year":"2011","unstructured":"Sorror, M. L. et al. Long-term outcomes among older\n                                    patients following nonmyeloablative conditioning and allogeneic\n                                    hematopoietic cell transplantation for advanced hematologic\n                                    malignancies. JAMA\n                                    306, 1874\u20131883\n                                    (2011).","journal-title":"JAMA"},{"key":"261_CR3","unstructured":"Howlader N. N. A. et al. SEER Cancer Statistics Review, 1975\u20132014\n                                    (Bethesda, MD, National Cancer Institute, 2017). http:\/\/seer.cancer.gov\/csr\/1975_2014\/."},{"key":"261_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3109\/07853890.2014.952662","volume":"46","author":"M Hamadani","year":"2014","unstructured":"Hamadani, M. Autologous hematopoietic cell\n                                    transplantation: an update for clinicians. Ann. Med.\n                                    46, 619\u2013632\n                                    (2014).","journal-title":"Ann. Med."},{"key":"261_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","volume":"5","author":"AS Kanate","year":"2019","unstructured":"Kanate, A. S. et al. Maintenance therapies for\n                                    hodgkin and non-hodgkin lymphomas after autologous\n                                    transplantation: a consensus project of ASBMT, CIBMTR, and the\n                                    lymphoma working party of EBMT. JAMA\n                                        Oncol.\n                                    5, 715\u2013722\n                                    (2019).","journal-title":"JAMA Oncol."},{"key":"261_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.14046","volume":"174","author":"TS Fenske","year":"2016","unstructured":"Fenske, T. S. et al. Allogeneic transplantation\n                                    provides durable remission in a subset of DLBCL patients\n                                    relapsing after autologous transplantation. Br. J. Haematol.\n                                    174, 235\u2013248\n                                    (2016).","journal-title":"Br. J. Haematol."},{"key":"261_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","volume":"32","author":"TS Fenske","year":"2014","unstructured":"Fenske, T. S. et al. Autologous or\n                                    reduced-intensity conditioning allogeneic hematopoietic cell\n                                    transplantation for chemotherapy-sensitive mantle-cell lymphoma:\n                                    analysis of transplantation timing and modality. J. Clin. Oncol.\n                                    32, 273\u2013281\n                                    (2014).","journal-title":"J. Clin. Oncol."},{"key":"261_CR8","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith, S. M. et al. Hematopoietic cell\n                                    transplantation for systemic mature T-cell non-hodgkin lymphoma.\n                                        J. Clin. Oncol.\n                                    31, 3100\u20133109\n                                    (2013).","journal-title":"J. Clin. Oncol."},{"key":"261_CR9","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.bbmt.2015.07.028","volume":"21","author":"E Klyuchnikov","year":"2015","unstructured":"Klyuchnikov, E. et al. Reduced-intensity\n                                    allografting as first transplantation approach in\n                                    relapsed\/refractory grades one and two follicular lymphoma\n                                    provides improved outcomes in long-term survivors. Biol. Blood Marrow Transplant.\n                                    21, 2091\u20132099\n                                    (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"261_CR10","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2018018531","volume":"2","author":"NN Shah","year":"2018","unstructured":"Shah, N. N. et al. Outcomes of medicare-age\n                                    eligible NHL patients receiving RIC allogeneic transplantation:\n                                    a CIBMTR analysis. Blood Adv.\n                                    2, 933\u2013940\n                                    (2018).","journal-title":"Blood Adv."},{"key":"261_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo, A. et al. Defining the intensity of\n                                    conditioning regimens: working definitions. Biol. Blood Marrow Transplant.\n                                    15, 1628\u20131633\n                                    (2009).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"261_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for\n                                    malignant lymphoma. J. Clin.\n                                        Oncol.\n                                    25, 579\u2013586\n                                    (2007).","journal-title":"J. Clin. Oncol."},{"key":"261_CR13","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka, D. et al. 1994 Consensus conference on\n                                    acute GVHD grading. Bone Marrow\n                                        Transplant.\n                                    15, 825\u2013828\n                                    (1995).","journal-title":"Bone Marrow Transplant."},{"key":"261_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman, H. M. et al. Chronic graft-versus-host\n                                    syndrome in man. A long-term clinicopathologic study of 20\n                                    Seattle patients. Am. J. Med.\n                                    69, 204\u2013217\n                                    (1980).","journal-title":"Am. J. Med."},{"key":"261_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cmpb.2007.07.010","volume":"88","author":"X Zhang","year":"2007","unstructured":"Zhang, X., Loberiza, F. R., Klein, J. P. &\n                                    Zhang, M. J. A SAS macro for estimation of direct adjusted\n                                    survival curves based on a stratified Cox regression model.\n                                        Comput. Methods Programs\n                                        Biomed.\n                                    88, 95\u2013101\n                                    (2007).","journal-title":"Comput. Methods Programs Biomed."},{"key":"261_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmpb.2010.07.005","volume":"101","author":"X Zhang","year":"2011","unstructured":"Zhang, X. & Zhang, M. J. SAS macros for\n                                    estimation of direct adjusted cumulative incidence curves under\n                                    proportional subdistribution hazards models. Comput. Methods Programs Biomed.\n                                    101, 87\u201393\n                                    (2011).","journal-title":"Comput. Methods Programs Biomed."},{"issue":"9","key":"261_CR17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","volume":"22","author":"Timothy S. Fenske","year":"2016","unstructured":"Fenske T. S., et al. Allogeneic hematopoietic cell\n                                    transplantation as curative therapy for patients with\n                                    non-hodgkin lymphoma: increasingly successful application to\n                                    older patients. Biol. Blood Marrow\n                                        Transplant.\n                                    22, 1543\u20131551\n                                    (2016).","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"261_CR18","unstructured":"National Coverage Determination (NCD) for Stem Cell\n                                    Transplantation (Formerly 110.8.1) (110.23) 2016 [updated\n                                    1\/27\/2016. Available from: https:\/\/www.cms.gov\/Medicare\/Coverage\/Coverage-with-Evidence-Development\/."},{"key":"261_CR19","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror, M. L. et al. Hematopoietic cell\n                                    transplantation (HCT)-specific comorbidity index: a new tool for\n                                    risk assessment before allogeneic HCT. Blood.\n                                    106, 2912\u20132919\n                                    (2005).","journal-title":"Blood."},{"key":"261_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.bbmt.2018.01.015","volume":"24","author":"N Epperla","year":"2018","unstructured":"Epperla, N. et al. Survival of lymphoma patients\n                                    experiencing relapse or progression after an allogeneic\n                                    hematopoietic cell transplantation. Biol. Blood Marrow Transplant.\n                                    24, 983\u2013988\n                                    (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"261_CR21","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3324\/haematol.2016.156356","volume":"102","author":"HJ Khoury","year":"2017","unstructured":"Khoury, H. J. et al. Improved survival after acute\n                                    graft-versus-host disease diagnosis in the modern era. Haematologica.\n                                    102, 958\u2013966\n                                    (2017).","journal-title":"Haematologica."},{"key":"261_CR22","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","volume":"34","author":"N Ghosh","year":"2016","unstructured":"Ghosh, N. et al. Reduced-intensity transplantation\n                                    for lymphomas using haploidentical related donors versus\n                                    HLA-matched sibling donors: a center for international blood and\n                                    marrow transplant research analysis. J.\n                                        Clin. Oncol.\n                                    34, 3141\u20133149\n                                    (2016).","journal-title":"J. Clin. Oncol."},{"key":"261_CR23","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","volume":"127","author":"AS Kanate","year":"2016","unstructured":"Kanate, A. S. et al. Reduced-intensity\n                                    transplantation for lymphomas using haploidentical related\n                                    donors vs HLA-matched unrelated donors. Blood.\n                                    127, 938\u2013947\n                                    (2016).","journal-title":"Blood."},{"key":"261_CR24","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-14-2221","volume":"21","author":"EA Chong","year":"2015","unstructured":"Chong, E. A. et al. Combination of lenalidomide and\n                                    rituximab overcomes rituximab resistance in patients with\n                                    indolent B-cell and mantle cell lymphomas. Clin. Cancer Res.\n                                    21, 1835\u20131842\n                                    (2015).","journal-title":"Clin. Cancer Res."},{"key":"261_CR25","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn, L. H. et al. Obinutuzumab plus bendamustine\n                                    versus bendamustine monotherapy in patients with\n                                    rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a\n                                    randomised, controlled, open-label, multicentre, phase 3 trial.\n                                        Lancet Oncol.\n                                    17, 1081\u20131093\n                                    (2016).","journal-title":"Lancet Oncol."},{"key":"261_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/bjh.13101","volume":"168","author":"M Furtado","year":"2015","unstructured":"Furtado, M., Johnson, R., Kruger, A., Turner, D.\n                                    & Rule, S. Addition of bortezomib to standard dose chop\n                                    chemotherapy improves response and survival in relapsed mantle\n                                    cell lymphoma. Br. J.\n                                        Haematol.\n                                    168, 55\u201362\n                                    (2015).","journal-title":"Br. J. Haematol."},{"key":"261_CR27","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood.V120.21.686.686","volume":"120","author":"WH Wilson","year":"2012","unstructured":"Wilson, W. H. et al. The Bruton's Tyrosine Kinase\n                                    (BTK) Inhibitor, Ibrutinib (PCI-32765), has preferential\n                                    activity in the ABC subtype of relapsed\/refractory de novo\n                                    diffuse large B-cell lymphoma (DLBCL): interim results of a\n                                    multicenter, open-label, phase 2 study. Blood.\n                                    120, 686\n                                    (2012).","journal-title":"Blood."},{"key":"261_CR28","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal, A. K. et al. PI3Kdelta inhibition by\n                                    idelalisib in patients with relapsed indolent lymphoma.\n                                        N. Engl. J. Med.\n                                    370, 1008\u20131018\n                                    (2014).","journal-title":"N. Engl. J. Med."},{"key":"261_CR29","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz, S. M. et al. Objective responses in\n                                    relapsed T-cell lymphomas with single-agent brentuximab vedotin.\n                                        Blood.\n                                    123, 3095\u20133100\n                                    (2014).","journal-title":"Blood."},{"key":"261_CR30","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1002\/ajh.25403","volume":"0","author":"A Levin","year":"2019","unstructured":"Levin, A. & Shah, N. N. Chimeric antigen\n                                    receptor modified T cell therapy in B cell non-Hodgkin\n                                    lymphomas. Am. J. Hematol.\n                                    0, S18\u2013S23\n                                    (2019).","journal-title":"Am. J. Hematol."},{"issue":"Suppl 1","key":"261_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1182\/blood-2018-99-110747","volume":"132","author":"VA Chow","year":"2018","unstructured":"Chow, V. A. et al. Outcomes of patients with large\n                                    B-cell lymphomas and progressive disease following CD19-specific\n                                    CAR T-cell therapy. Blood\n                                    132(Suppl 1), 94\n                                    (2018).","journal-title":"Blood"},{"key":"261_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","volume":"12","author":"N Epperla","year":"2019","unstructured":"Epperla, N. et al. Allogeneic hematopoietic cell\n                                    transplantation provides effective salvage despite refractory\n                                    disease or failed prior autologous transplant in\n                                    angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J. Hematol. Oncol.\n                                    12, 6 (2019).","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"261_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/blood-2018-01-791335","volume":"132","author":"Norbert Schmitz","year":"2018","unstructured":"Schmitz N., Lenz G., Stelljes M. Allogeneic\n                                    hematopoietic stem cell transplantation (HSCT) for T-cell\n                                    lymphomas. Blood\n                                    132, 245\u2013253\n                                    (2018).","journal-title":"Blood"},{"key":"261_CR34","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.bbmt.2014.03.013","volume":"20","author":"BL McClune","year":"2014","unstructured":"McClune, B. L. et al. Allotransplantation for\n                                    patients age >\/=40 years with non-Hodgkin lymphoma:\n                                    encouraging progression-free survival. Biol. Blood Marrow Transplant.\n                                    20, 960\u2013968\n                                    (2014).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"261_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbmt.2018.08.025","volume":"25","author":"C Kyriakou","year":"2019","unstructured":"Kyriakou, C. et al. The impact of advanced patient\n                                    age on mortality after allogeneic hematopoietic cell\n                                    transplantation for non-hodgkin lymphoma: a retrospective study\n                                    by the european society for blood and marrow transplantation\n                                    lymphoma working party. Biol. Blood\n                                        Marrow Transplant.\n                                    25, 86\u201393\n                                    (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"Suppl 1","key":"261_CR36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1182\/blood-2018-99-111143","volume":"132","author":"Y-B Chen","year":"2018","unstructured":"Chen, Y.-B. et al. A phase 1b study of intravenous\n                                    vedolizumab plus standard of care for graft-versus-host disease\n                                    prophylaxis in subjects undergoing allogeneic hematopoietic stem\n                                    cell transplantation for hematologic malignancies: 6-month\n                                    results. Blood.\n                                    132(Suppl 1), 605\n                                    (2018).","journal-title":"Blood."},{"issue":"3, Supplement","key":"261_CR37","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.bbmt.2018.12.130","volume":"25","author":"M Jagasia","year":"2019","unstructured":"Jagasia, M. et al. Ruxolitinib in combination with\n                                    corticosteroids for the treatment of steroid-refractory acute\n                                    graft-vs-host disease: results from the phase 2 REACH1 trial.\n                                        Biolo. Blood Marrow\n                                        Transplant.\n                                    25(3, Supplement), S52\n                                    (2019).","journal-title":"Biolo. Blood Marrow Transplant."}],"updated-by":[{"DOI":"10.1038\/s41408-021-00472-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0261-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0261-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0261-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:15:42Z","timestamp":1671207342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0261-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0261-1","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41408-021-00472-w","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,3]]},"assertion":[{"value":"14 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-021-00472-w","URL":"https:\/\/doi.org\/10.1038\/s41408-021-00472-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Hamadani reports; Research Support\/Funding:\n                                    Takeda Pharmaceutical Company; Otsuka Pharmaceutical; Spectrum\n                                    Pharmaceuticals; Astellas Pharma. Research Funding to\n                                    Institution: Janssen R&D, Celgene Corporation, Merck,\n                                    MedImmune, Seattle Genetics, and Millennium Pharmaceuticals.\n                                    Consultancy: MedImmune LLC; Janssen R&D; Incyte Corporation;\n                                    ADC Therapeutics; Cellerant Therapeutics; Celgene Corporation;\n                                    Pharmacyclics & DOVA Oncology, Magenta Therapeutics, Omeros.\n                                    Speaker\u2019s Bureau: Celgene Corporation (Inactive); Sanofi\n                                    Genzyme. Dr. Shah reports receiving honoraria and\/or travel\n                                    support from Incyte, Celgene, and Lentigen Technology; serving\n                                    on scientific advisory boards for Kite, Celgene, and Cellectar;\n                                    receiving institutional research support for clinical trials\n                                    from BMS and Miltenyi Biotec. None of the authors have any\n                                    competing interests in the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"97"}}